General Partner

New Ventures Funds

Passionate about business transformations that accelerate growth, efficiencygains, cost reductions, and competitive advantage formarket leaders as wellas up-and-coming innovators with next-generation ideas

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending.

He currently serves as General Partner at New Ventures Funds. Before joining New Ventures Funds, he served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories.

Mr. Glorikian holds an MBA from Boston University and a bachelor’s degree from San Francisco State University. Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston GlobeBioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets. He is also the Author of two books: Commercializing Novel IVD’s; A Comprehensive Manual for Success and MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market.

Sessions

DAY 1 / ‏‏‎ ‎

08:30 AM - 09:00 AM
Plenary View Session
Description

Chairman’s Opening Remarks

Smart Pharma: Key Trends that are Transforming Drug Discovery and Development

This opening session will set the stage for the discussions that will take place over the course of the Summit and identify the key trends that are taking hold in biopharma and reshaping drug discovery and clinical development. Themes will include:

  • Reduced timelines and improved accuracy of prediction of safety and efficacy
  • Diversified drug pipelines with new targets and drug re-purposing
  • Challenges: data sharing, access to reliable, robust data, and establishing new standardization
  • The dynamics of the continually evolving partnership ecosystem – biopharma, technology platforms, CROs, investors, regulatory and patients.
Chair
Harry Glorikian, General Partner, New Ventures Funds
Author: MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market

DAY 2 / ‏‏‎ ‎

12:55 PM - 1:00 PM
Plenary

Closing Remarks

Speaker
Harry Glorikian, General Partner, New Ventures Funds
Author: MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market

Never miss an announcement